Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MARQIBO KIT vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed after two or more anti-leukemia therapies
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life ranges from 19 to 40 hours (mean 23 hours) in adults. The prolonged half-life in Marqibo (liposomal vincristine) is due to the sustained release from the liposomal formulation, allowing once-weekly dosing.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Primarily hepatic metabolism via CYP3A4; also undergoes biliary excretion.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Primarily hepatobiliary excretion; approximately 5-16% of the dose is excreted unchanged in the urine over 72 hours. Fecal excretion accounts for about 10% of the administered dose, with the remainder undergoing extensive hepatic metabolism and biliary elimination.
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Approximately 75% bound to plasma proteins, primarily to albumin and beta-globulins.
82–88% bound to plasma proteins (primarily albumin).
Volume of distribution (Vd) is 4.0-7.9 L/kg (mean 5.6 L/kg), indicating extensive tissue binding and distribution into tissues, consistent with its lipophilic nature.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Not applicable; Marqibo is administered intravenously only. Oral bioavailability is negligible (<5%) due to extensive first-pass metabolism and P-glycoprotein efflux.
Oral: 65–80% (median 73%)
No specific dose adjustment guidelines. Use caution in patients with creatinine clearance <50 m L/min due to potential for increased exposure.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh B), reduce dose to 1.8 mg/m2 every 7 days. Mild impairment (Child-Pugh A): no adjustment necessary.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
Safety and efficacy not established in patients <18 years. Data limited to case reports; no standard dosing guidelines available.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
No specific dose adjustment based on age alone. Monitor closely for increased toxicity (e.g., neurotoxicity, myelosuppression) due to potential for decreased organ function and comorbidities.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
MARQIBO is for intravenous use only. Fatal if given intrathecally. Use only with a medical provider experienced in the administration of chemotherapeutic agents. Contains vincristine sulfate, a vesicant. Ensure proper administration technique.
None
Extensive extravasation precautions required; neurotoxicity (peripheral neuropathy, autonomic neuropathy); hematologic toxicity (myelosuppression); gastrointestinal toxicity (constipation, ileus); hepatic impairment; monitor serum uric acid levels; embryo-fetal toxicity.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to vincristine or any component of the formulation; patients with demyelinating conditions (e.g., Charcot-Marie-Tooth syndrome); intrathecal administration.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 and alter drug levels. Avoid St. John's wort as it may induce CYP3A4 and reduce efficacy. No specific food restrictions other than these. Maintain adequate hydration to prevent tumor lysis syndrome.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
No data on presence in human milk. M/P ratio not determined. Due to potential for serious adverse reactions in nursing infants, discontinue breastfeeding during treatment and for at least 2 weeks after last dose.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
No established dose adjustments for pregnancy due to lack of studies. Pharmacokinetic changes (increased volume of distribution, decreased clearance) may necessitate dose modifications based on tolerability and response. Use lowest effective dose.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
MARQIBO KIT (vincristine sulfate liposome injection) is indicated for adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory acute lymphoblastic leukemia (ALL). It is a liposomal formulation of vincristine that prolongs drug exposure and enhances tumor delivery. Administer intravenously over 1 hour at a dose of 2.25 mg/m² without a maximum dose cap, unlike standard vincristine. Do not substitute for other vincristine formulations. Monitor for neurotoxicity, including peripheral neuropathy, autonomic neuropathy (constipation, ileus), and cranial nerve palsies. Premedicate with corticosteroids and antiemetics. Avoid concomitant use of strong CYP3A4 inducers or inhibitors due to altered metabolism. Neurotoxicity is dose-limiting and may require dose reduction or discontinuation. Tumor lysis syndrome may occur; ensure adequate hydration and allopurinol. Pregnancy category D; verify pregnancy status. Extravasation management is similar to other vinca alkaloids (apply heat, hyaluronidase).
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
This medication is a form of chemotherapy given intravenously for a type of leukemia.,It may cause nerve damage; report numbness, tingling, pain, weakness, or constipation immediately.,Do not receive any live vaccines during treatment and for 6 months after.,Use effective contraception during treatment and for at least 1 month after the last dose.,Avoid grapefruit juice and St. John's wort while on this medication.,Drink plenty of fluids to prevent tumor lysis syndrome.,Report any signs of infection (fever, chills) or bleeding (easy bruising, black stools).
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MARQIBO KIT vs AGRYLIN, answered by our medical review team.
MARQIBO KIT is a Antineoplastic Agent that works by Vinca alkaloid that binds to tubulin, inhibiting microtubule assembly and mitotic spindle formation, causing metaphase arrest in dividing cells.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MARQIBO KIT and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MARQIBO KIT is: 2.25 mg/m2 intravenously over 1 hour every 7 days. Maximum dose per administration is 3.6 mg.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MARQIBO KIT and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MARQIBO KIT is classified as Category C. Pregnancy Category D. First trimester: high risk of embryofetal toxicity including malformations (neural tube, cardiac, skeletal defects) and spontaneous abortion. Second and third. AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.